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transplantation, with two thirds developing CKD by 10 years. The
majority of patients had stage 3 disease. However, echoing obser-
vations in the non-transplant setting, this moderate CKD (GFR
<60 ml/min/1.73 m2) was clinically relevant having implications
for survival [2,3].
There are several points worthy of comment. First, although
there was clearly a progressive deterioration in renal function
with time after transplant, the greatest loss occurred within the
ﬁrst year. The authors speculate that this reﬂects nephrotoxic
immunosuppressive drugs. Little mention was made of the role
of peri-operative acute kidney injury (AKI). In our unit, despite
optimized pre-transplant renal function and less calcineurin
inhibitor exposure in recent years, patients are experiencing more
GFR loss from baseline to 1-year [4]. This is in the context of a rise
in the incidence of AKI that has occurred in parallel with a marked
rise in the use of higher risk grafts [4]. We have hypothesized that
graft injury may play a critical role in the pathogenesis of AKI in
this setting. It is well recognized that AKI can cause permanent
structural damage, with progressive tubulo-interstitial ﬁbrosis
and long-term repercussions for renal function [5]. Therefore,
we suggest that in addition to renal sparing immunosuppression,
future strategies to prevent CKD may include therapies that
minimize the renal hit at time of transplantation.
Second, the apparent lack of era effect on the frequency of
CKD is interesting. United States registry data has shown that
the introduction of MELD has been accompanied by an increased
likelihood of end-stage kidney disease, which has been attributed
to greater pre-operative renal dysfunction [6]. Nevertheless,
given that the adjusted hazard ratio for renal failure only rose
by 15% after MELD implementation, one might not anticipate a
demonstrable difference in this comparatively small study. With-
out detailed information, regarding additional recipient and
donor factors, it is difﬁcult to draw any real conclusions regarding
the evolving incidence of CKD. Readers should not be falsely reas-
sured by this data, especially in the face of an escalating use of
higher risk grafts.
Finally, a major conclusion of the study by Allen et al. was the
limited reliability of creatinine-based GFR estimation in
predicting mortality in these patients, and that preventative
and expectant management, based on the early recognition of
renal dysfunction, may require actual measurement of GFR. We
argue that measured GFR is time-consuming, costly and not an
applicable test for most transplant centres when repeated tests
are necessary. Although a useful research tool, a single absolute
measure of renal function in an individual patient is less relevant
than delta estimated GFR for modifying clinical care.
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Letters to the EditorReply to: ‘‘Chronic kidney disease after liver transplantation’’
To the Editor:
We appreciate the insightful comments of Leithead and Ferguson
regarding our recent analysis of prevalence of chronic kidney
disease (CKD) after liver transplantation (LT). We agree that
peri-operative acute kidney injury (AKI) contributes to the devel-
opment of chronic kidney disease after LT in a proportion of
patients. We did not ascertain the trajectory of renal function
in the early postoperative period in all our subjects. Since the ﬁrst
iothalamate clearance measurement was performed at 4 months
post-transplantation, we chose this interval as the ﬁrst point in
our time-dependent analysis. Our assumption that in the major-
ity of cases the renal dysfunction is attributed to calcineurin-
inhibitor nephrotoxicity was derived from the detailed chart
review of a small subset of patients with normal renal function
at the time of LT who developed CKD at 4 months. In this random
sample, only 27% of patients had postoperative AKI, deﬁned as
increase in creatinine by 0.3 mg/dl from baseline [1]. Thus, while
we acknowledge that postoperative AKI contributes to post-LT
CKD, we cannot quantify the degree to which it contributes to
CKD based on our data. We wholeheartedly agree that, given
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the signiﬁcant impact of perioperative AKI on post-LT outcomes
[2], every attempt to prevent and reverse it in a timely manner
should be made.
Leithead and Ferguson also suggest to cautiously interpret our
ﬁnding concerning the lack of increase in post-LT CKD in the
MELD era, which is discordant with other studies of the national
database [3]. While registry databases provide a large sample
size, they are limited by available data (e.g., measured GFR), lack
of standardization (e.g., assay for serum creatinine), and
completeness (e.g., loss to follow-up). As a single centre study,
we can only report what we observed in our patients – post-
transplant CKD is clearly an important comorbidity; whether
our practice of vigilant monitoring and early intervention was
responsible for the lack of the trend observed in other studies,
remains uncertain.
It may be worth noting that the organ allocation system
should not affect the biological incidence of renal morbidity in
transplant candidates. The primary reason that more patients
are transplanted with reduced renal function is the worsening
organ shortage, which results in more patients developing com-
plications of advanced cirrhosis, such as hepatorenal syndrome
and AKI. The MELD score identiﬁes these patients as their renal
function deteriorates and facilitates access to LT. Should renal
function not be a part of the allocation scheme, further progres-
sion of renal dysfunction would result in increased requirements
for simultaneous kidney transplantation or higher rates of with-
drawal from the waiting list. The net effect of the MELD-based
allocation may be a reduction in these poor waitlist outcomes
at the expense of an increase in incidence of end-stage renal
disease (ESRD), although our data did not show this trend.
Lastly, we agree that directly measured GFR is not a conve-
nient way to monitor our patients long-term. However, we do
believe that clinicians tend to underutilize other measures of
GFR, such as creatinine clearance or serum cystatin-C. Likewise,
an important message in this paper is that serum creatinine or
estimated GFR (often automatically reported by the laboratory)
should not be interpreted in isolation. Changes over time in cre-
atinine or eGFR may help the astute clinician to identify or at
least suspect CKD. Unfortunately, the current CKD classiﬁcation
[4] does not encompass changes in serum creatinine and the
diagnosis of CKD may be missed, due to absent vigilance of the
transplant physician.
Shunt dysfunction: Is it suitable as the primary end point
in transjugular intrahepatic portosystemic shunt trials?
To the Editor:
We read with great interest the randomized controlled trial (RCT)
by Perarnau et al. that was published in the Journal of Hepatology
[1]. The ﬁrst RCT on transjugular intrahepatic portosystemic
shunt (TIPS), comparing PTFE-covered stents (CS) with bare
stents (BS) on shunt patency and clinical outcomes, was
published in 2004 [2]. Ten years later, Perarnau et al. concluded
that CS provided a signiﬁcant reduction in shunt dysfunction
compared to BS. No doubt, this paper has provided additional
evidence to conﬁrm the advantages of CS. However, we still
believe that certain issues merit further discussion.
To begin with, the shunt dysfunction rates in this paper (31.5%
and 44.0% in the CS group vs. 53.8% and 63.6% in the BS group
after 1 and 2 years) were higher than those in the ﬁrst RCT
(12.8% and 34% in the CS group vs. 43.9% and 74% in the BS group
after 1 and 2 years) [1,2]. The authors attribute the outcome var-
iance to differences in patient selection and shunt diameter [1].
However, this explanation may be incomplete. For example, the
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